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Cancer is a disease involving loss of cellular growth control and disruption of cell
differentiation. Recent approaches to therapy for various types of cancer have focused on
drugs that induce the differentiation of maturation-resistant cells causing the disease
(Stevens et al., 1990). Some compounds such as retinoic acid, which inhibit the Epstein-
Barr virus activation induced by tumor promoters (Tokuda et aI., 1986; Nishino et al.,
1988), have been shown to act as inhibitors of tutnor promotion in vitro (Verma et al.,
1980). Furthermore, it is known that retinoids can suppress the process of carcinogenesis
in vivo in experimental animals and prevent human solid tumors (Sporn and Roberts, 1983;
Hong et al., 1990; Lee et aI. 1993). Clinical trials of differentiation-inducing agents in
patients with leukemia, Inyelodysplastic syndromes, and solid tumors have included the
use of t-RA and it's metabolites. These agents induce complete or partial remissions of
some kinds of tumors (Breitman and He, 1990).
However, all of these retinoids exhibited considerable toxicity and the desired
therapeutic potential has not been achieved (Roberts et aI., 1994). Consequently, if new
compounds could be found with good efficacy, but tnuch less toxicity compared with most
natural retinoids, a significant advance might be realized in the control of cell differentiation
as related to cancer treatment. On the basis of such considerations, a group of new
compounds named "heteroarotinoids" has been synthesized in recent years.
Heteroarotinoids, which are modified on the basis of arotinoids, contain aromatic ring(s)
and at least one heteroatom within the skeletal framework (Spruce et aI., 1987). Recently,
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heteroarotinoids have shown important anticancer activity and much lower or equal toxicity
when compared to t-RA, 13-c-RA, and (E)-4-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-
2-hephthalenyl)-I-propenyl]benzoic acid, also known as TTNPB (Spruce and Berlin,
1994). (E)-p-[2-(4,4-dimethylchroman-6-yl)propenyl]benzoic acid, also known as LWS-
3, is a new compound of this heteroarotinoid family. Recent data have-shown that it is
approximately equal in toxicity to t-RA, but 630-940 fold less toxic than TTNBP (Spruce
and Berlin, 1994). More interestingly, this compound has a binding affinity for retinoic
acid receptors (Benbrook, 1995).
The objective of the present study was to evaluate the effect of the specific
heteroarotinoid, LWS-3, on the induction of F9 cell differentiation. The F9 mouse
teratocarcinoma cells were used as a model system to study cell differentiation and to






The term, "retinoids" is a general term that refers to both naturally occurring
compounds with vitamin A activity, including all-trans-retinol (vitamin A), retinal, and
retinoic acid (Figure 1), and synthetic analogs, with or without the biological activity,
(Sporn et al., 1984). The IUPAC-IUB Joint Commission on Biochemical Nomenclature in
1982 recommended that, "The term vitamin A should be used as the generic descriptor for
retinoids exhibiting qualitatively the biological activity of retinol. This term should be used
in derived terms such as vitamin A activity, vitamin A deficiency, vitamin A antagonist"
(IUPAC-IUB Joint Commission, 1982).
The existence of an essential nutritional factor, later termed vitamin A, was reported
and its physiological effects described long before the vitamin itself was isolated or its
chemical structure determined. McCollum and Davis reported that a fat-soluble substance
not only can promote rat growth but can also prevent xerophthalmia (McCollum and Davis,
1913). Drummond named this essential fat-soluble substance vitamin A in 1920
(Drummond, 1920). Subsequently, the determination of the chemical structure of ~-
carotene by Kerrer's group clarified the relationship between vitamin A in animals and
provitamin carotene in plants (Karrer et aI., 1930). Almost at the same time, Karrer et al.
first determined the structure of retinol using a highly purified vitamin A extract obtained
from shark liver oil (von Euler and Karrer, 1931). A decade later, Arens and Van Dorp









Figure 1. The Naturally-occt:..."';ng RetinolOs.
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the field of metabolism of natural retinoids accompanied by the rapid development of
analytical methods, especially high-performance liquid chromatography (HPLC).
A more detailed review of the "classical" discoveries in the field of vitamin A
research, including the original description of vitamin A, the recognition of carotenoid as a
provitamin, the elucidation of the chemical structure and then the total synthesis of naturally
occurring retinoids, unique pathology of both hypovitaminosis A and hypervitaminosis A
in experimental animals and men, the fundamental role of vitamin A in vision, and the
adequate nutrition in human and animals can be consulted in several references (Karrer and
Jucker, 1950; McCollum, 1957; Isler, 1971; Wald, 1968; and Wolf, 1980).
In the late 1970s, the discovery of additional biological activities, such as growth
promotion, reproduction, bone remodeling, and the induction of epithelial cell
differentiation, led to rapid progress in the field of retinoids. Retinoids are prime
candidates for cancer chemoprevention since they regulate cell proliferation and
differentiation and cancer is associated with abnormal growth and loss of differentiation
(Hicks, 1983). Within the last decade, the discovery of retinoid receptors as members of
the steroid receptor superfamily of transcription factors has spurred molecular approaches
in the study of retinoids. A variety of retinoid receptors have been discovered recently.
These receptors are ligand-dependent transcriptional factors which can activate many genes,
and repress the expression of other genes (Means and Gudas, 1995).
Retinoid-Binding Proteins and The Retinoid Receptors
In the late 1970s, Ong and Chytil first discovered a cellular retinoic acid-binding
protein (CRABP). They demonstrated that the binding protein was a small cytoplasmic
protein (Mr 15.5 kDa) that binds t-RA selectively and with high affinity (Kd =4 nM) (Ong
and Chytil, 1978). There are at least two species of this protein, CRABP I and CRABP II.
Both proteins have been well studied and both genes have been isolated. These two closely
related proteins show distinct patterns of expression in the adult as well as during
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development (Giguere et aI., 1990; Maden et aI., 1988). Cellular retinoic acid-binding
proteins are thought to prevent RA from interacting with the retinoic acid receptors.
Overexpression of CRABP I can reduce the ability of RA to stimulate transcription, and
also will decrease the rate of RA metabolism (Means and Gudas, 1995). The function of
CRABP II is less clear. The induction of the CRABP II gene by RA suggested that
CRABP II may function to sequester or degrade retinoids when high RA levels saturate
CRABP I (Astrom et aI., 1994). However, there is no direct evidence that CRABP can
regulate transcription by t-RA. Some cells can respond to t-RA without the binding
protein, and in these cells, t-RA can have effects that do not require CRABP (Mangelsdorf
et aI., 1990).
There is another type of protein that belongs to the retinoid-binding protein family,
the cellular retinol-binding proteins (CRBPs). Like retinoic acid-binding protein, CRBPs
are small and 10c3:lized in the cytoplasm. CRBPs also have two species, CRBP I and
CRBP II. Cellular retinol-binding proteins are thought to be involved in the metabolism of
retinol into retinyl esters, or into retinadehyde and then retinoic acid (Levin, 1993; Napoli et
aI., 1991). Thus, the CRBPs may facilitate the synthesis of active retinoids in the embryo.
In 1987, Petkovitch et al. and Giguere et al. reported that they isolated a human
orphan receptor cDNA which encoded the first known RA-activated transcription factor.
This human RA receptor (hRAR-a) has a DNA-binding domain and ligand-binding
domain, and can activate the transcription of target genes with t-RA at the effective
concentrations in vivo (Petkovitch et aI, 1987; Giguere et aI., 1987). Evans later found that
hRAR-a belongs to the family of nuclear receptors because the two domains of this
receptor are structurally and functionally conserved with other members of the nuclear
receptor superfamily (Evans, 1988). Now, three different subtypes of RARs (RAR-a,
RAR-P, and RAR-y) are known to exist in mammals, birds, and amphibians (Giguere et
al.~ 1987; Benbrook et aI., 1988; and Krust et aI., 1989). The ligand-binding domains of
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the RARs are highly conserved (>75% amino acid identity) suggesting that they all came
from a common ancestral RAR gene (Mangelsdorf et aI., 1994).
The second class of retinoid receptors, RXRs (retinoid "X" receptor) were
discovered in the early 1990s (Mangelsdorf et aI., 1990). cDNAs were isolated that
encoded three RXR proteins, termed RXR-a, RXR-~, and RXR-y. Like RARs, the
RXRs are closely related in both their DNA-binding and ligand-binding domains, and act
as sequence specific transcription factors for a variety of genes ( Mangelsdorf et aI., 1992;
Leid et aI., 1992).
The homologies of each class of retinoid receptor indicate that they likely bind
common ligands and regulate common target sequences. The RAR protein can bind to
t-RA and/or 9-c-RA (9-cis-RA). However, RXRs have a lower affinity for t-RA than do
the RARs. RXRs exhibit a higher affinity for 9-c-RA, a geometric isomer of t-RA
(Heyman et aI., 1992). All the members of the retinoid receptor family regulate gene
expression by binding to very similar DNA sequence elements called RAREs (RAR
response elements) and RXREs (RXR response elements) (Umesono et aI., 1988). These
elements consist of tandem repeats of a six base pair consensus sequence (AGGTCA)
separated by 1-5 base pairs of variable sequences. The strength of binding to each of the
receptors is affected by the slight variations in these hexamer sequences and in the distance
by which they are separated (Means and Gudas, 1995).
RARs and RXRs bind target genes and regulate transcription by forming homo- or
heterodimers. RXRs not only can form a heterodimer with RAR but can also serve as a
heterodimeric pattern with other members of the steroid hormone superfamily, such as the
thyroid hormone receptor (TR), vitamin D receptor (VDR), and peroxisome proliferation
activated receptor (PPAR) (Yu et aI., 1991; Kliewer et aI., 1992). The ability of RXR to
bind other receptors heterodimers establishes a central role for RXR in hormonal signaling
pathway. Mangesdorf et al. demonstrated two retinoid signaling pathways. RXR
homodimer is stabilized to favor the activation of RXR target genes at high 9-c-RA
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concentrations. When there is a low 9-c-RA concentration or a high RAR concentration or
both, the RAR-RXR heterodimer is stabilized. Because the RXR-RAR heterodimer has a
higher affinity for DNA than the RXR-RXR homodimer does, the heterodimer may
outcompete the homodimer for binding to RXREs (Mangelsdorf et aI., 1994).
In addition to receptor dimerization, the activity of the retinoid receptors may be
modulated by other nuclear transcription factors, and in particular by AP-1. AP-1 is a
complex of the proto-oncoproteins lun and Fos, whose activity is stimulated by tumor
promoters and growth factors. Recent studies suggest that RAR may form a nonproductive
complex with Iun, thereby inhibiting AP-1 transaction. These results provide a possible
mechanism for how RA can limit cell growth (Schule et aI., 1991; Nicholson et aI., 1990).
Every subtype of retinoid receptors has its distinct pattern of expression. In
general, RAR-a, RXR-a, and RXR-~ are all ubiquitously expressed and thus may mediate
retinoid signaling, while RAR-~, RAR-y, and RXR-y genes exhibit more limited patterns
of expression. The different patterns of expression suggest that individual subtypes of
RAR and RXR families plays an important role in diverse aspects of development, from
implantation of the embryo to organogenesis, limb development, and central nervous
system differentiation as well as in adult physiology and metabolism ( Mangelsdorf et aI.,
1994).
Metabolism of Retinol and Retinoic Acid
Metabolism of Retinol
All retinoids in the body originate in the diet either as plant carotenoid pigments,
such as ~-carotene, or as the long-chain retinyl esters found in animal tissue. Glover
indicated two pathways of carotenoid conversion to retinol in mammals in 1960: 1.
central oxidative cleavage of carotenoid to retinal, then reduction to retinol. Two soluble
enzymes are involved in this process: ~-carotene 15, 15-dioxygenase and retinaldehyde
reductase, and 2. excentric oxidative cleavage through a series of ~-apocarotenals to retinal,
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followed by reduction to retinol (Glover, 1960). In intestinal mucosa, the first pathway is
known to be the predominant one to retinol (Lakshman et aI., 1989). The enzymes
involved in excentric cleavage have not yet been reported.
Dietary retinyl esters are hydrolyzed in the intestinal lumen and intestinal mucosa.
Two enzymatic activities have been clarified. One of them, with hydrolase activity that
preferentially hydrolyzed short-chain retinyl esters, such as retinyl caproate. The other one
with hydrolytic activity is most likely to hydrolyze long-chain retinyl esters, such as retinyl
palmitate (Ong et al., 1987).
The retinol from the reduction of retinaldehyde or absorbed by the intestinal mucosa
is then converted to retinyl ester to nascent chylomicrons for uptake into the body (Quick
and Ong, 1990). Quick and Ong demonstrated that for the human intestinal Caco-2 cell
line, esterification of retinol requires that retinol bind to CRBP II first. Thus, CRBP II
plays a central role in directing and channeling dietary retinol into the general circulation
(Quick and Ong, 1990).
After being transported into the lymphatic system, nascent chylomicrons undergo
lipolysis catalyzed by lipoprotein lipase to convert them to chylomicron remnants
(Goodman and Blaner, 1984). After entering the plasma, chylomicrons acquire the C and
E apoliproteins from plasma high-density lipoproteins (HDL). The apoC II can activate the
enzyme lipoprotein lipase, beginning with the hydrolysis of chylomicron core triglycerides
resulting in the shrinkage of the chylomicron core and transfer of redundant surface
components into HDL (Green and Glickman, 1981). Fatty acids produced by lipolysis can
either circulate as free fatty acids bound to serum albumin or are taken up by adjacent
tissues for oxidation or reesterification (Goodman, 1984). These processes form
chylomicron remnants (Redgrave, 1983). Most chylomicron remnants are removed from
circulation by the liver (Mahely and Hussian, 1991).
The liver plays a major role in the body in the uptake and metabolism of newly




retinoid storage and metabolism: the parenchymal cells and steller cells (Blaner et aI., 1985;
Batres and Olson, 1987). The parenchymal cells are directly involved in uptake of
chylomicron remnants and in the synthesis and secretion of RBP. The steller cells are
major storage cells for retinyl esters in the liver (Hendricks et aI., 1988). Hendricks et aI.
indicated that the retinyl esters of chylomicron remnants are first hy-drolyzed in the
parenchymal cells and then transferred to the steller cells for storage (Hendricks et aI.,
1988). Recently, Gad and Harrison reported that a retinyl ester hydrolase localized in the
parenchymal cell plays an important role in hydrolysis of newly absorbed dietary retinyl
ester. The hydrolysis is very quick after the chylomicron remnant is taken up by the
hepatic parenchymal cell (Gad and Harrison, 1991). In addition to hydrolysis of retinyl
esters, the parenchymal cells are the major cellular site for the synthesis and secretion of
RBP in the liver (Yamada et aI., 1987). Some dietary retinol may be directly secreted into
circulation, bound to newly synthesized RBP. The remainder of the dietary retinol will be
transported to the steller cells for storage (Yamada et al., 1987).
During hepatic storage and metabolism, retinyl esters are hydrolyzed and esterified
to long-chain fatty acid esters by lecithin:retinol acyltransferase (LRAT) and acyl-
CoA:retinol acyltransferase (ARAT) (Randolph et aI., 1991). Randoph et ai. demonstrated
that when retinol and fatty acid CoA were present at the normal concentrations, LRAT
played a predominate role in catalyzing the formation of retinyl esters. However, if the
concentrations of retinol or fatty acid CoA are much higher, ARAT might playa larger role
in retinol esterification (Randolph et aI., 1991).
The questions of how the retinol is transferred between parenchymal cells, stellate
cells~ and plasma is still unsolved. Several hypotheses were proposed (Blaner and Olson,
1994). (1) The RBP is solely responsible for the intracellular transfer and release of
retinoids in the cells. (2) An unidentified protein carrier plays a crucial role in intercellular
transfer. (3) The retinol is transferred directly between perenchymal and stellate cells by
means of membrane contacts.
10
Since the nuclear receptors for RA have been discovered, scientist have paid
increasing attention to the processes that generates and maintains cellular RA levels. Blood
plasma t-RA can be derived from dietary sources and from endogenous metabolism in
tissues. Most cells and tissues seem to have the ability to oxidize retinol to RA. However,
the biochemical process by which RA is enzymatically formed within tissues from the
oxidation of retinol is still unknown. The current hypothesis is that retinol is first oxidized
to retinaldehyde, then oxidized to RA (Blaner and Olson, 1994). Although the alcohol
dehydrogenase (ADH) of liver can catalyze the oxidation of retinol to retinaldehyde
(Zachman and Olson, 1961) and the aldehyde oxidase can convert retinaldehyde to RA
(Frolik, 1984), the exact role of these two enzymes in the conversion of retinol to RA is
unclear.
13-c-RA and 9-c-RA are metabolites of t-RA produced in vivo. These isomers are
active in mediating RA function. Cullum and Zile indicated that 13-c-RA was a naturally
occurring metabolite of t-RA. They injected a dose of t-RA intrajugularly into vitamin A-
depleted rats and found 13-c-RA in the plasma and small intestine within 2 minutes after
injection (Cullum and Zile, 1985). However, little is known about the enzymatic formation
and catabolism of the 13-c- and 9-c-isomers.
Induction of Differentiation of F9 Teratocarcinoma Cells by Retinoids
Teratocarcinomas are malignant tumors composed of a large variety of sometimes
highly organized and well-differentiated cell types derived from all three primary germ
layers (Stevens, 1967). Characteristically, these tumors contain a rapidly dividing,
undifferentiated cell population known as embryonal carcinoma cells which are the stem
cells for the differentiated cells and which are responsible for the formation of the tumor.
Embryonal carcinoma cells have been isolated from primary cultures of cells
derived from teratocarcinomas, and from these cells, several clonal cell lines have been
developed. The relationships between embryonal carcinoma cells, early embryonic cells ..
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and teratocarcinomas have been established (Martin, 1981). These relationships indicate
that the embryonal carcinoma cell system can serve as a model for the study of early
embryonic development and the regulation of gene expression which is involved in this
process.
F9 is a clonal embryonal carcinoma cell line which is mostly used as a model to
study the control of differentiation by retinoids, since F9 stem cells show very low
spontaneous differentiation into two stages of mammalian cell development (Strickland and
Saway, 1980). Strickland and Mahdavi (1978) first showed that treatment with t-RA can
induce differentiation of F9 cells very efficiently. This differentiation can be induced at
concentrations of t-RA as low as 10-9 M. The process of F9 cell differentiation induced by
t-RA can be divided into two stages. In the presence of t-RA, F9 cells differentiate first
into endoderm cells with marked changes in morphology, stimulation of plasminogen
activator secretion, synthesis of new types of collagen, and disappearance of the cell
surface antigen SSEA-l (Strickland et aI., 1980; Evain and Anderson, 1981). After the
first differentiation stage, the F9 endoderm cells have the potential to express the parietal
endoderm phenotype in low density cultures or in the presence of dibutyryl cAMP,
whereas in suspension or high density cultures they express the visceral endoderm
phenotype (Hogan et aI., 1981). However, in the absence of t-RA, elevation of cAMP
levels has no effect on the differentiation of F9 cells (Strickland et aI., 1980). Wang and
Gudas (1983) have demonstrated that t-RA treatment of F9 cells causes an increase in the
level of collagen IV and laminin B mRNA expression. Treatment with both t-RA and
dibutyryl cAMP further elevates the mRNA level, whereas single dibutyryl cAMP has no
effect. Retinoids have been found to be very effective inducers of differentiation of almost
every embryonal carcinoma cell line tested (Jetten, 1986). It has been demonstrated that
both retinoic acid and retinol can induce differentiation (Jetten and Deluca, 1983; Eglitis and
Sherman, 1983).
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The levels of a variety of different transcription factor genes are altered by t-RA
treatment of F9 cells. The SPARC gene is one of these transcription factor genes and it has
been widely used as a marker to monitor the differentiation of F9 cells induced by t-RA
(Gudas et aI., 1994). Mason et aI. (1986b) reported that the expression of the SPARC
gene was increased approximately 20-fold in response to the t-RA and dibutyryl cAMP. In
F9 stem cell differentiating into parietal endoderm in response to t-RA and dibutyryl cAMP
there was a small decrease during the first 24 hours, followed by a 20-fold increase in
SPARC mRNA levels over the next 5.5 days. They also indicated that the differentiation
of F9 cells into parietal endoderm was accompanied by an increase in SPARC gene
transcription (Mason et aI., 1986b). The SPARC gene is positively regulated by t-RA via
sequences in its promoter, although the exact sequences have not been identified (McVey et
aI., 1988).
The SPARC gene was cloned and the protein encoded by this gene, SPARC
protein, was characterized in 1986. It is a Mr 43,000 secreted, acidic, cysteine-rich,
calcium-binding glycoprotein homologous to 43K bovine endothelial 'culture shock'
protein (Mason et aI., 1986a). It is encoded by a single gene localized in the central region
of mouse chromosome II (Mason et aI., 1986b). Recently, this protein has been identified
as a member of a group of proteins that exert anti-spreading effects on various cultured
cells (Everitt and Sage, 1992). SPARC can induce the expression of type I plasminogen
activator inhibitor (PAl-I) in cultured bovine aortic endothelial cells (Hasselaar et aI.,
1991), and can inhibit the binding of PDGF-BB and PDGF-AB complexes to the PDGF
receptor on human dermal fibroblasts (Raines et aI., 1992). Other transcription factor
genes of F9 cells modulated by retinoids include the Hox 1.6 gene_ Hox 1.1 gene, jun
Family gene, etc. (Means and Gudas, 1995).
13
Synthetic Retinoids
The fundamental role of retinoids in controlling the state of cellular differentiation
and preventing excessive proliferation raises the possibility that these compounds may be
useful in inhibiting carcinogenesis, for the treatment of cancer, and for dermatological
diseases such as psoriasis. Though retinoids might be valuable as- noncytocidal
chemotherapeutic agents, their high toxicity prevents their use conventionally or for a
prolonged period. In addition, the retinoids thus far known are lipophilic, are very slowly
eliminated from the body, cause serious prolonged toxicity, and in particular, teratogenic
effects. Great interest has been generated in the last decade in the production of synthetic
retinoids with better therapeutic effects and lower toxicities. The basic structure of
retinoids consist of three portions: a cyclic end group, a polyene side chain, and a polor end
group (Figure 2). Synthetic retinoids have been developed based on the alteration in one or
more parts of the basic retinoid skeleton (Lippman and Meyskens Jr., 1988). Extensive
chemical modification of retinoic acid led to the synthesis of arotinoids. The most
extensively studied arotinoid is (£)-4-[2-(5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-
hephthalenyl)-l-propenyl]benzoic acid, also known as TTNPB. These compounds are
very potent in several standard screening tests and in the treatment of keratinizing and
hyperproliferative disorders including psoriasis (Tsambaos et ai. 1990).
Heteroarotinoids (Figure 2) are a class of newly synthesized retinoids which
normally consist of at least one aryl ring and a heteroarotom within the retinoid skeletal
framework (Spruce et aI., 1987). Several separate assays, including the tracheal organ
culture (TOC) assay, the ornithine decarboxylase (ODC) assay and the ability to induce the
differentiation of human promyelocytic cells, are usually used to examine the activities of
synthetic retinoids. The heteroarotinoids have been shown to have remarkable activities in
these standard assays (Dawson et aI., 1984; Spruce et aI., 1987). Preliminary studies also
demonstrated that the heteroarotinoids (X=O, R=ET) supported growth and were active in
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Figure 2. Synthetic Retinoids
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(Thome et aI., 1993). Compared with other retinoids, a diaryl heteroarotinoid (Figure 3),
LWS-3 (X=O, R=H), was reported to be approximately equal in toxicity to t-RA but 630-
940- fold less toxic than TTNPB. Thus, the discovery of retinoid nuclear-receptor-protein
families and the identification of their cell specificities have promoted the search for
receptor-selective retinoic acid analogs that would selectively bind to and .then activate a
particular receptor. Using 9-c-RA as a control, LWS-3 was reported to have affinity for
the ~,y-receptors (Benbrook, 1995). It is appropriate to consider heteroarotinoids as a new
selective ligand that can interact with specific receptors to regulate gene expression. The
objective of the present study was to evaluate the effect of this heteroarotinoid, LWS-3, on




Preparation of Tissue Culture Plates
Before the F9 mouse teratocarcinoma cells were seeded, the tissue culture plates
were coated with 0.1 % sterile porcine skin gelatin solution. The 0.1 % gelatin solution
(Fisher) was autoclaved and allowed to cool to room temperature, and autoclaved again to
destroy the possible fungal spores (Darrow et aI., 1990). This sterile solution can be
stored at 4 DC for several months. The sterile gelatin solution was added to tissue culture
plates (Falcon), refrigerated for 2 hours at 4 oC, then the solution was removed by
aspiration, and washed 3 times, using sterile distilled water. Treated plates can be stored at
room temperature.
Maintaintance and Subculture of the Cells
The F9 mouse teratocarcinoma cell line was purchased from American Type Culture
Company (ATCC CRL-1720). After thawing rapidly (within 40-60 seconds) in a 37 °C
water bath, the cells were seeded at a density of 3 x 105 cells per 100 mm diameter cell
culture plate and incubated in a 10% C02 incubator. Dulbecco's modified Eagle's medium
(DMEM) containing 15% (v/v) fetal bovine serum and antibiotics (see Table 1) was used to
maintain all F9 cell cultures. The medium was mixed well and sterilized through a 0.22 Jlm
filter. After 3 days of growth, the cells were subcultured. The DMEM was removed by
aspiration, 4-5 ml of fresh trypsin (O.25%)-EDTA (5 X 10-4 M) was added to rinse the
cells for 1-2 minutes and then removed. The cell culture was kept at room temperature until
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Table 1
Compositions of Cell Culture Medium for F9 Teratocarcinoma Cells
Stock solutions (Sigma) Medium (1000 ml)
- -
Dulbecco's Modified Eagle's Medium 850ml
Fetal Bovine Serum 150ml




the cells detached from the plate entirely. Five milliliters of fresh DMEM was added and
collected in a plastic conical centrifuge tube and centrifuged at about 300xg for 10-15
minutes. The pellet was resuspended in 2 ml of fresh medium. The culture was
vigorously pipetted up and down using a 10 ml syringe with a 21.5 gauge needle. It was
crucial to obtain a single cell suspension. A single cell suspension was -seeded in 10 ml
DMEM at a density of 3 x 105 cells per 100 mm diameter plate.
Preparation of Retinoic Acid and the Selected Heteroarotinoid
All-trans-retinoic acid, t-RA (Sigma), was stored as a powder at -20 0C in a
lightproof container. It was dispensed in the dark and dissolved in 100% ethanol at a
concentration of 3.0 mg/m!. The 3.0 mg/ml stock was diluted 1:10 in 100% ethanol and
finally 1:100 in DMEM to prepare a 10-5 M stock solution. The heteroarotinoid (E)-P-[2-
(4,4-dimethylchroman-6-yl)propeny]benzoic acid (LWS-3) was synthesized by Dr.
Berlin's group in the Department of Chemistry, Oklahoma State University (Figure 3). A
absolute ethanol used to dissolved the compounds has no effect on the morphological
change of the F9 cells at the concentration below 0.1 % (Benbrook, 1995). Like the
preparation of retinoic acid, it was weighed in the dark to prepare a 10-2 M stock solution,
diluted in 100% ethanol to get a 10-3 M and 10-4 M solution and then 1: 100 in DMEM to
prepare the 10-5 M and 10-6 M heteroarotinoid solutions. The maximum ethanol
concentration in the culture medium was 0.1 % with LWS-3 at 10-6 M with dilutions to
0.001 % at 10-9 M. All the procedures after ethanol dilution were carried out under sterile
conditions.
Induction of F9 Teratocarcinoma Cells
As a positive control for F9 cell differentiation into primitive extraembryonic
endoderm, the cells were treated with 1 x 10-7 M t-RA at a density of 3 x 105 cells per 100







Figure 3. The Structures of the Heteroarotinoid LWS-3 and All-trans-
Retinoic Acid (t-RA)
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concentrations from 10-6 M to 10-9 M. The F9 cells without t-RA or LWS-3 were used as
negative control. After 84 hours incubation, the morphology of the F9 cell was
investigated through a reverse-phase microscope.
RNA Isolation
Total RNA was isolated using the Chomezynski/Sacchi single step method
(Chomezynski and Sacchi, 1987) with the following modification. The cell culture
medium was removed by aspiration and the cells were rinsed with 10 ml of cold phosphate
buffered saline (PBS). PBS (1 ml) was added to each plate and the cells were scraped off
using a rubber policeman. The cells were resuspended and lysed by vortexing in 0.4 ml of
guannidinium thiocyanate solution containing 4 M guannidinium thiocyanate (Sigma), 25
mM sodium citrate pH 7, 0.5% sarcosyl and 0.1 mM 2-mercaptoethanol. Twenty seven
microliters of 3 M sodium acetate, pH 4.0 was added and mixed well by vortexing. Then
the cells were extracted with an equal volume of water saturated phenol and
chloroform:isoamyl alcohol (49:1). After vortexing for 10 seconds and cooling on ice for
10 minutes, the cells were centrifuged for 5 minutes at 14,000xg and the aqueous phase
was collected carefully. The cells were precipitated with an equal volume of isopropanol
and incubated for at least 2 hours at -20 0C. The mixture was centrifuged again for 10
minutes at 14,000xg. The pellet was carefully washed twice with 75 % ethanol and once
with 100 % ethanol. The pellets were air dried and the RNA was dissolved in DEPC-
treated water. The concentration of RNA was quantitated by measuring the absorbance at
260 nanometers.
SPARC Plasmid Purification
The plasmid containing SPARe gene was a gift kindly provided by Dr. Benbrook,
Health Sciences Center, The University of Oklahoma. The plasmids were transfonned into
E. coli DH5 cells and screened by ampicilin resistance. The transformed DRS cells, which
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propagate plasmids at high copy numbers, grew in LB medium containing appropriate
ampicilin overnight at 37 0C. For purification of the plasmid DNA, Promega Wizard™
(Promega) Miniprep kit was used according to the instructions of manufacturer, except that
the DNA pellet was finally dissolved in 48°C TE buffer. The concentration was measured
by measuring absorbance at 260 nanometers.
Digestion of Plasmid DNA Containing the SPARC Gene
One microgram of purified plasmid DNA containing the SPARC gene was digested
by the restriction endonuclease PvuII (GIBeO BRL) at 37 0C for 1 hour. The digestion
products were then separated on a 1.5% agarose gel using TAE as a running buffer. The
size of the fragment was estimated by comparison with the standard 1 Kb ladder. The
digestion product expected at 415 bp was then excised from the agarose gel and extracted
with QIAGEN gel extraction kit (QIAGEN) as described in the manufacture's guide.
Labeling of the Probe
The 415 bp fragment was then non-radioactively labeled using the Genius DIG
DNA labeling kit (Boehringer Mannheim). A tube containing a 150 ng fragment of DNA
was placed in a boiling water for 10 minutes, then transferred immediately to ice. The
DNA was mixed well with sterile distilled water, lOX hexanucleotide mixture, dNTP
mixture, and Klenow enzyme in the order listed. The labeled DNA was then incubated at
37 °C overnight. The next morning, the labeled DNA was extracted and dissolved in 50 Jll
of TE buffer. Just prior to completing the prehybridization, the probe was heated in boiling
water for 10 minutes and diluted with cold prehybridization solutions.
Northern Hybridization
The 1.5 % agarose formaldehyde gel was prepared the day before running. The
DEPC treated MOPS running buffer was used to cover the gel overnight. It was a very
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efficient method to deactivate any RNase. RNA (10 flgllane) was electrophoresed through
a 1.5% agarose formaldehyde gel in MOPS running buffer. Two and half hours later, the
gel was photographed under V.V. light and then blotted onto a nylon membrane
(MagnaGraph) overnight at room temperature.
After blotting, the membrane was crosslinked for 2 minutes and prehybridized in
prehybridization solution at 42 oe for at least 2 hours with agitation. After the
prehybridization, the solution was discarded and the diluted SPARe gene probe was added
to hybridize with the membrane at 42 oe overnight. After several washes with wash
solution and maleate buffer, the membrane was incubated in 50 ml of Northern Blocking
Solution for 2 hours at room temperature with agitation to stop the hybridization
completely. Fifty mililiters of diluted anti-digoxigenin-alkaline phosphatase was incubated
with the membrane for 30 minutes. After the membrane was equilibrated with genius
buffer, the membrane was placed DNA side down on the top of one clear overhead sheet to
which 0.4 ml lumi-phos 530 had been added. The membrane was moved up and down
and side to side carefully to distribute the reagent over the surface. The membrane was
then exposed to X-ray film (Kodak) at room temperature for 2 to 4 hours, depending on the
strength of the signal.
Slot Blot Hybridization
A series of four 2X dilution of the same concentrations of RNA isolated from the
F9 cells treated with different concentrations of drugs were performed. The original
concentration of RNA was 5 flgllOO fll. RNA (100 fll) was denatured by adding 300 fll of
6.15 M formaldehyde in lOX sse and heated at 65 oe for 5 minutes. The Nylon
membranes were soaked in sterile distilled water, then in lOX sse, and the slot apparatus
was assembled. Samples of 400 fll were loaded into the slot, and aspirated through the
Nylon membrane, washed with 400 1-11 lOX sse and aspirated again. The Nylon
membrane was UV crosslinked and baked at 80 oe in vacuum for 2 hours. The membrane
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was hybridized with DIG-ll-dUTP labeled SPARe DNA fragment following the





To study the morphological changes of the F9 teratocarcinoma stem cell caused by
the treatment of a selected heteroarotinoid (LWS-3), F9 cells were grown in the Dulbecco's
modified Eagle's medium contained 15% PBS. As a negative control, the cells were
grown in the cell culture without any drug or ethanol treatment. At the same time, the F9
stem cells grown in the culture presented with 10-7 M t-RA were used as positive control.
All of the drugs used to treat F9 cells should be made fresh from the stock solution, since
the retinoic acid is not stable in the medium.
F9 stem cells grown in the culture without any drug treatment are closely packed
colonies of embryonal carcinoma cells (Figure 4 A). The cell population appears
predominately homogenous, although some cells were occasionally observed with different
morphology. The positive control F9 embryonal carcinoma cells assume a flat morphology
characterized by cytoplasmic granules and more cell colonies were triangular (Figure 4 B)
after the 10-7 M t-RA was presented to the culture (Strickland and Mahdavi, 1978).
The F9 carcinoma cells were maintained in the DME medium which contained 10-6
M to 10-9 M concentrations of LWS-3. After incubation for 84 hours, the cells were
photographed and the effect of LWS-3 on F9 cell morphology was investigated. The
LWS-3 brought about morphological alterations of F9 stem cells to the differentiated state.
After the cells were treated with the LWS-3 for 84 hours, the cells moved apart from one
another., became larger, triangular, more spread out, and accumulated intracellular granules
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Figure 4.
Morphology of F9 Teratocarcinoma Cells after Treatment with LWS-3 for
84 Hours.
The F9 teratocarcinoma cells were seeded in the culture medium (Table 1) at a density of 3
x 105 cells per 100 mm diameter petri dish in the presence or absence of different
concentrations of LWS-3 for 84 hours. (A) Negative control (no drug); (B) Positive
control (10-7 M t-RA); (C) 10-6 M LWS-3; (D) 10-7 M LWS-3; (E) 10-8 M LWS-3; (F)10-9
MLWS-3.
A: No drug treatment
B: 10-7 M t-RA treatment
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c: 10-6 M LWS-3 treatment
D: 10-7 M LWS-3 treatment
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E: 10.8 M LWS-3 treatment
F: 10.9 M LWS-3 treatment
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(Figure 4, C-F). The appearance of these cells closely resembles the presumptive
endoderm derived from teratocarcinoma embryoid bodies (Martin and Evans, 1975). This
evidence suggests that LWS-3 can induce the F9 stem cell to differentiate from embryonal
carcinoma into endoderm carcinoma. However, it is difficult to distinguish the difference
in morphology of the differentiated F9 cells treated with the different concentrations of
LWS-3.
Isolation of RNA from the F9 Cell Culture
To prepare the RNA for northern blotting, the RNA was isolated from the F9 cell
culture which had been treated with various concentrations of the heteroarotinoid, LWS-3,
10-7 M t-RA or no drug for 84 hours.
The RNA was isolated from the cell culture using modified single-step method as
described. After purification, the RNA concentration was quantitated by measuring the
absorbance at 260 nm and purity was checked by measuring the ratio of absorbance at both
260 nm and 280 nrn and by agarose formaldehyde gel electrophoresis. Only the RNA with
a ratio of 260 nrn and 280 nm greater than 1.65 was used in the further hybridization (data
not shown). To check whether the RNA isolated from the cell was pure enough for a
northern blot, 5 J..lg of RNA was electrophoresed through 1.5% agarose formaldehyde gel.
The results (Figure 5) showed that the two ribosomal RNA subunits of 18S and 28S could
be clearly identified after the gel electrophoresis. This confirmed that no RNA degraded
during the process.
However, as shown in the Figure 5, there was still some smear of the isolated RNA
after the gel electrophoresis. Since high quality RNA is crucial for the northern blot, more
phenol-chloroform was added for extraction to get higher quality RNA, but it was still not
purified as expected after gel electrophoresis. Moreover, the RNA was isolated using
TRlzol Total RNA Isolation Reagent from GrBCO BRL to get higher quality RNA.
Although it was quick and easy to use, this reagent apparently was not reliable for F9 cell
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Figure 5
1.5 % Agarose Formaldehyde Gel of RNA Isolated from F9 Teratocarcinoma
Cells in the Presence or Absence of LWS-3 for 84 hours.
F9 cells were plated at a density of 3 X 105 cells per 100 mm diameter petri dish in the
medium (Table 1) in the presence or absence of LWS-3. After 84 hours incubation, RNA
was isolated from F9 cells using the modified single-step method. RNA (10 Jlg) was then
electrophoresed through 1.5% agarose formaldehyde gel at 100 V for 2 hours. Lane 1:
RNA ladder; Lane 2: Negative control (no drug); Lane 3: Positive control (10-7 M t-RA);
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RNA isolation (Data not shown). The isolated RNA was not pure enough and there was
some DNA and protein that interfered. The ratio of 260 nm and 280 nm of isolated RNA
was between 1.40 to 1.60. More seriously, a lot of sticky silk-like unknown substances
existed in the RNA so that the RNA couldn't be dissolved well. So finally, the modified
single-step method was chosen to isolate RNA because the smear of the RNA did not affect
the result of northern hybridization as shown in Figure 10 and 11.
Probe Preparation for Hybridization
cDNA sequence of SPARC gene mRNA expressed after the F9 cells treated with
retinoic acid was obtained by Mason et al in 1986 (Mason et aI., 1986a). The eDNA
sequence of the SPARC gene is shown in Figure 6. The restriction enzyme Pvull digested
the sequence motifs from nucleotide 385 (CAG) to nucleotide 800 (CTG). The resulting
415 bp product was used as the probe. Figure 7 shows the result of Pvull digestion after
the 1.5% agarose gel electrophoresis. The size of the DNA fragment after digestion was
estimated according to the 1 Kb standard ladder. As shown on the Figure 7, one fragment
of 415bp was separated by the agarose gel after electrophoresis as expected. Since the
vector sequence was not known, it was very difficult to recognize the other three bands
(band 1, 2, 3). These bands were probably the fragments of the vector digested by PvuII
since there are only two cut sites of PvuII on the SPARC gene. But the 415 bp fragment
was the exact product of PvuII digestion of the SPARC gene. To prepare the probe for the
northern hybridization, the 415 bp product of PvuII digestion of the SPARC gene was
extracted and then labeled using the random priming method described before for the
further hybridization. The sequence of the probe was also shown in Figure 6 (385nt-
800nt).
Using DIG nonradioactive labeling of the probe for the hybridization is a safe and
easy method compared to using 32p to label the probe. Furthermore, the probe can be
reused several times and kept at -200C for over a year. However, one important
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Figure 6.
































































Restriction Digestion of Plasmid DNA Containing the SPARe Gene.
One microgram of plasmid DNA containing the SPARC gene was digested with the
restriction enzyme, PvuII. The digested plasmid DNA was electrophoresed on a 1.5%
agarose gel at 90 V for 3 hours. The sizes (bp) of selected band of the plasmid DNA
containing the SPARe gene and standards (1 Kb ladder) are shown. Lane 1: 1 Kb DNA






shortcoming of this method is that the yield of the probe DNA which has been labeled can
not be detected directly after labeling and extraction. Attempts to detect the yield of the
probe labeled through the agarose gel electrophoresis was unsuccessful. No bands of the
probe were seen on the gel since the yield was too low (Data not shown). For this reason,
it is possible that there was not enough probe for the detection of the· hybridization,
although the Genius detection kit is very sensitive.
Northern Hybridization
It is hard to judge the effect of LWS-3 on induction of F9 cells when depending
only on the morphological change, since the alteration of the cell morphology was subtle.
To examine the effect of induction of the F9 cells differentiation at the molecular level and
more precisely, differentiation marker genes have been used to study gene transcription
associated with F9 cell differentiation (Gudas et aI., 1994). For these reasons, expression
of the differentiation specific gene SPARC was chosen to investigate the effect of the
heteroarotinoid LWS-3 on induction the F9 cell differentiation. The PvuII digestion
product 415 bp fragment of the SPARC gene was labeled and was used as the probe with
northern hybridization (Figure 7). RNA (10 Jlg) was isolated from the F9 cells treated with
different agents and loaded on the gel. After electrophoresis through 1.5% agarose
formaldehyde gel at 100 V for 2 hours, the RNA on the gel was then blotted onto Nylon
membranes and the membranes were then hybridized with the probe overnight. The results
were detected using the Genius Detecting Kit described before.
Figure 8 shows the differentiation specific SPARC gene expression profiles of F9
cells after drug treatment for 84 hours. As the negative control, the F9 cells were incubated
in the normal medium without any drugs. After 84 hours incubation, the expression of the
SPARC gene was at a very low level, almost not expressed (Lane 1). However in the
presence of 10-7 M t-RA and 10-6 M of LWS-3, the SPARC gene expression increased
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Figure 8.
Northern Hybridization of RNA Isolated from F9 Teratocarcinoma Cells in
the Presence or Absence of 10.6 M LWS·3 with the SPARC gene.
F9 cells were plated at a density of 3 X 105 cells per 100 mm diameter petri dish in the
medium (Table 1) in the presence or absence of LWS-3. After an 84 hour incubation,
RNA was isolated from F9 cells using the modified single-step method. RNA (10 Jlg) was
electrophoresed through 1.5% agarose formaldehyde gel at 100 V for 2 hours. The RNA
on the 1.5% agarose formaldehyde gel was transferred onto a nylon membrane by northern
blotting. The membrane was then hybridized with a labeled 415 bp SPARC gene probe.
The size of bands was estimated by the position compared with I8S and 28S RNA
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Northern Hybridization of RNA Isolated from F9 Teratocarcinoma Cells in
the Presence of Different Concentrations of LWS-3 for 84 Hours with the
SPARC Gene.
F9 cells were plated at a density of 3 X 105 cells per 100 mm diameter petri dish in the
medium (Table 1) in the presence of different concentrations of LWS-3. Mter an 84 hour
incubation, RNA was isolated from F9 cells using the modified single-step method. RNA
(10 J.lg) was electrophoresed through 1.5% agarose formaldehyde gel at 100 V for 2 hours.
The RNA on the 1.5% agarose formaldehyde gel was transferred onto a nylon membrane
by northern blotting. The membrane was then hybridized with a labeled 415 bp SPARC
gene fragment. The size of bands was estimated by the position compared with 18S and
28S RNA subunits (Wang and Gudas, 1983). Lane 1: 10-7 M t-RA; Lane 2: 10-6 M LWS-
3; Lane 3: 10-7 M LWS-3; Lane 4: 10-8 M LWS-3; Lane 5: 10-9 M LWS-3.
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4 2.2 kB
dramatically. (Lane 2 and 3). Figure 9 shows the results of the SPARC gene expression
after the F9 cells were treated with different concentrations of LWS-3 for 84 hours. As
shown in Figure 9, with increasing concentrations of LWS-3, SPARC gene expression
increased (Lane 2-5). The highest concentration of LWS-3 (10-6 M) caused the largest
expression among the different concentrations of LWS-3 in this experiment (Lane 5).
The size of the hybridized transcript can be estimated from its position relative to the
18S and 28S ribosomal RNA (Wang and Gudas, 1983). Mason et al. (1986b) indicated
that the F9 cell induces a 2.2 kb SPARC mRNA expression after differentiation. Using this
method, we estimated the size of the gene transcription after the F9 cells were treated with
LWS-3. As shown in Figure 8 and 9, the expressed SPARC mRNA after the LWS-3
induction was 2.2 Kb. These results indicate that the heteroarotinoid (LWS-3) can induce
the differentiation marker gene SPARC expression. Along with the observation of F9 cell
morphology change, it confirmed the results that LWS-3 can induce F9 cell differentiation.
Slot Blot Hybridization
To quantitate the effects of different concentrations of LWS-3 on induction of
SPARC gene expression, a series of four 2X dilutions of the same concentrations of RNA
isolated from F9 cells treated with different concentrations of LWS-3 were blotted onto the
Nylon membrane and the northern slot blot was performed. Figure 10 shows the results of
slot blot hybridization after the cells were treated with the LWS-3 for 84 hours. The probe
used in the slot blot was the same as that in the northern hybridization. As shown in Figure
10, the hybridization was detected as bands on the film. Incubation of LWS-3 for 84 hours
(Pattern C, D, E, F) increased SPARC mRNA expression at the different level compared
with the negative control (Pattern A). These data are consistent with the results of the
northern hybridization and indicate that the heteroarotinoid can induce differentiation of
SPARC gene expression. From densitomer scans of the film of Figure 10, the
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Figure 10. Northern Slot Blot of RNA Isolated from F9
Teratocarcinoma Cells in the Presence or Absence of Different
Concentrations of LWS-3 for 84 hours with the SPARC gene.
F9 cells were plated at a density of 3 X 105 cells per 100 mm diameter petri dish in the
medium (Table 1) in the presence or absence of LWS-3. After 84 hours of incubation,
RNA was isolated from F9 cells using the modified single-step method. A series of
four 2 X dilution of concentration of 5 ~g/l00 III RNA isolated from the F9 cells
treated with the different drug were transferred onto a Nylon membrane through the slot
apparatus. The membrane was hybridized with the SPARC gene probe. Pattern A:
Negative control (no drug); Pattern B: Positive control (10-7 M t-RA); Pattern C: 10-6
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levels of the SPARC gene expression can be quantitated. Figure 11 shows the results of
SPARC gene expression level after the selected heteroarotinoid (LWS-3) treatment of F9
cells for 84 hours. The Optical Density of each band was measured by densitomer scaning
and only those O.D. values in the linear range were selected and calculated. The SPARC
gene expression level was represented by the average value of O.D. in -the linear range
multiplied by the factor of dilution. However, in the cases of treatment of 10-7 M t-RA and
10-6 M LWS-3, the gene expressions of the four dilutions were saturated (Pattern Band
C). So the O.D. value of the most diluted concentration of the sample was selected and
multiplied by a dilution factor of 8 to calculate the SPARC gene expression level. These
results represented the least gene expression level after the F9 cells were treated with 10-7
M t-RA and 10-6 LWS-3. As shown in Figure 11, after F9 cells were treated with 10-7 M
t-RA, the SPARC gene expression was increased at least 11 fold (Bar B) compared to the
negative control (Bar A). Different concentrations of LWS-3 exhibited different effects on
induction of SPARC gene expression. Among the four concentrations of LWS-3 tested,
10-6 M LWS-3 showed the strongest effect and increased SPARC gene expression at least
7 fold (Bar C). 10-9 M LWS-3 exhibited the weakest effect on induction of the cell
differentiation and increased the SPARC gene expression about 3 fold (Bar F). This
confirms the finding that the selected heteroarotinoid LWS-3 can induce differentiation in





Effects of Different Concentrations of LWS·3 on Induction of SPARC Gene
Expression after the F9 Cells Were Exposed to LWS·3 for 84 Hours.
The film of slot blot (Figure 10) was scanned by pdi densitomer Model DNA 35. SPARC
gene expression level was represented by the average Optical Density values which were in
the linear range after scanning. Crossed bars (Bar B and C) represented the least SPARC
gene expression. Bar A: Negative control (no drug); Bar B: Positive control (10-7 M t-
RA); Bar C: 10-6 M LWS-3; Bar D: 10-7 M LWS-3; Bar E: 10-8 M LWS-3; Bar F: 10-9 M
LWS-3. See p39 for additional explanations.
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The property of certain anticancer drugs to induce cellular differentiation has made a
great impact on the search for new and more effective strategies for cancer therapy, and has
elicited many in vitro studies aimed at a better understanding of cell proliferation and
differentiation (Egorin, 1988). Retinoids are among the drugs actually involved in clinical
trials as anticancer drugs, since they regulate cell proliferation and differentiation, and
cancer is associated with abnormal growth with loss of differentiation. However, the full
therapeutic potential of this class of compounds has yet to be achieved because of the
associated toxicity at pharmacological levels. The search continues for more effective
drugs that can be used as chemopreventive agents of cancer.
Recently, heteroarotinoids, which are synthesized based on the structure of
retinoids, have shown some potential anticancer function. Some heteroarotinoids have
demonstrated an ability to support cell growth, reverse cornification of vaginal epithelial
cells in ovariectomized vitamin A-deficient rats (Thorne, 1993) and inhibit some tumor cell
growth (Benbrook, 1995). Furthermore, one selected heteroarotinoid, LWS-3, has shown
toxicity equal to t-RA, but far less than synthesized arotinoids (Spruce and Berlin, 1994).
The objective of the present study was to investigate the effect of a selected heteroarotinoid,
LWS-3, on cell differentiation using embryonal carcinoma F9 cells as a model system.
This study should help in our understanding of the role of newly synthesized
heteroarotinoids in the control of cell differentiation as related to cancer treatment.
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II
We have shown that the selected heteroarotinoid, LWS-3, brought about a
morphological alteration of F9 stem cells into the endoderm differentiation stage (Figure 4).
This resembles the differentiation of an endoderm-like cell induced by t-RA. The results
show that LWS-3 induces differentiation in the F9 stem cell.
To determine whether the morphological change of F9 cells wa-s the result of
differentiation, the expression of a differentiation specific gene, SPARC, was examined.
The transcription of the SPARC gene was increased after treatment by LWS-3 (Figure 8).
Even at the lowest concentration, LWS-3 showed some effects on induction of SPARC
gene expression. These results suggest that the selected heteroarotinoid, LWS-3, like
t-RA, can act as a differentiation agent.
The SPARC gene was selected as a marker to study the level of transcription factor
gene alteration during F9 cell differentiation. We have shown here that the SPARC gene
fulfills this criterion. From the data in this study, there is little doubt that the overall
increase in SPARC RNA levels is due, at least in part, to an increase in gene transcription
after treatment of the F9 stem cell with the heteroarotinoid, LWS-3.
The SPARC gene has been studied as a differentiation marker gene for a long time.
When the F9 stem cell was induced to differentiate from embroyl carcinoma to parietal
endoderm carcinoma cell, SPARC gene expression increased about 20 fold. When F9 cells
were induced to differentiate with t-RA, the parietal endoderm stage occurred after
dibutyryl cAMP was subsequently added into the cell culture of the primitive endoderm F9
cells induced by the t-RA treatment. Treatment of the primitive endoderm F9 cell with t-RA
alone at high density caused the F9 cell to aggregate and undergo differentiation to the
visceral endoderm cell. In this situation, SPARC gene expression was found to have a
transient decrease followed by an increase which plateaued after 4 days. However, there
was no direct data to show the SPARC gene expression level after the F9 stem cells
differentiated into the primitive endoderm stage by the induction of retinoic acid. In this
study, we showed that the SPARC gene expression increased at least 11 fold when the F9
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stem cell differentiated into the primitive endoderm stage induced by t-RA (Figure 11).
These results support the finding that SPARC gene expression increased 20 fold when the
F9 stem cell differentiated to parietal endoderm cell after the cell treated with t-RA and
cAMP for 5.5 days.
In this project, the F9 stem cells were treated with different drugs for 84 hours
without the presence of any cAMP in the cell culture. There are two reasons: 1. At a
density of 3 x 105 cells per 100 mm diameter plate, the F9 cells started to aggregate when
the cells were treated with t-RA and different concentrations of LWS-3 after 4 days
incubation (Data not shown). 2. The main objective for this project was to study the effect
of LWS-3 on induction of F9 cell differentiation, not to determine the exact differentiation
stages ofF9 stem cell induced by LWS-3. To evaluate the effect of LWS-3 on induction of
F9 cell differentiation, the cells were compared to those cells only treated with t-RA in this
project. No cAMP was used to treat the F9 cells. The results of the cell morphological
change and increased level of differentiation marker gene expression strongly suggest that
LWS-3 induces F9 stem cell differentiation. Even at the 10-9 M , the LWS-3 still showed
some abilities to induce cell differentiation.
The effects of a selected heteroarotinoid, LWS-3, to induce F9 mouse
teratocarcinoma cells differentiation have been studied in this project, and the changes in the
patterns of SPARC gene expression between undifferentiated and differentiated cells have
been well characterized. Following the LWS-3 treatment of F9 cells, one of the response
genes is SPARC. The increased expression of the SPARC gene in LWS-3 treated F9 cells
may be a potentially regulatory event in a gene cascade since the SPARC gene can induce
the expression of type I plasminogen activation inhibitor (PAI-1) in cultured bovine aortic
endothelial cells (Hasselaar et aI, 1991), and can inhibit the binding of PDGF-BB and
PDGF-AB complexes to the PDGF receptor on human dermal fibroblasts (Raines et aI.,
1992). Also, the SPARC gene encodes a calcium-binding glycoprotein that has been
identified as a member of a group of proteins that exert anti-spreading effects on various
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cell cultures. An understanding of the induction of SPARC gene expression by LWS-3
will help us to study the mechanism of regulation of other genes in the process of cell
differentiation.
However, the actual molecular mechanism by which the heteroarotinoid modulates
SPARC gene expression and cell differentiation is still obscure. Retinoids. are thought to
produce their biological effects by interacting with specific nuclear receptors for RA (Leid
et al., 1992). These receptors are members of the steroid/thyroid superfamily of receptors
and as such are ligand-dependent transcription factors (Evans, 1988). There are distinct
ligand specificities of each of the receptor families, RAR and RXR. The RXR family of
receptors binds 9-c-RA (Heyman et aI., 1992) while the RARs can bind t-RA and 9-c-RA
(Allenby et aI., 1993). Thus, there are multiple retinoid receptors and multiple ligand
pathways. Disruption of RARy gene in the F9 cells does not affect the retinoic acid
induction of SPARC gene transcription (Boylan et aI., 1993). This result suggested that
the RARy is not directly responsive to retinoic acid for regulation of the SPARC gene
expression. LWS-3 has been shown to have a binding affinity for the RAR~ and RARy
receptors. If it is true that LWS-3 regulates SPARC gene expression through binding to
the RARp receptors, is the selected heteroarotinoid, LWS-3, a ligand for specific
receptors? All of these predictable phenomena that occur during the differentiation of F9
cells remains to be shown.
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